Cerity Partners LLC Has $1.46 Million Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Cerity Partners LLC lifted its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 32.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,005 shares of the medical device company's stock after buying an additional 18,529 shares during the period. Cerity Partners LLC owned about 0.11% of Tandem Diabetes Care worth $1,456,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Tandem Diabetes Care by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock valued at $267,989,000 after purchasing an additional 77,451 shares during the last quarter. ArrowMark Colorado Holdings LLC boosted its position in Tandem Diabetes Care by 14.1% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock valued at $98,108,000 after purchasing an additional 337,026 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Tandem Diabetes Care by 189.0% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company's stock valued at $59,830,000 after buying an additional 1,086,337 shares during the last quarter. Park West Asset Management LLC lifted its position in shares of Tandem Diabetes Care by 49.5% in the fourth quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock valued at $57,632,000 after buying an additional 530,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Tandem Diabetes Care by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,533,828 shares of the medical device company's stock valued at $55,261,000 after buying an additional 8,012 shares during the last quarter.

Tandem Diabetes Care Price Performance

Tandem Diabetes Care stock traded up $0.13 during mid-day trading on Friday, reaching $15.57. 202,074 shares of the company were exchanged, compared to its average volume of 1,565,078. The company has a fifty day simple moving average of $19.00 and a 200-day simple moving average of $23.17. Tandem Diabetes Care, Inc. has a 12 month low of $14.31 and a 12 month high of $47.60. The company has a debt-to-equity ratio of 1.99, a current ratio of 2.30 and a quick ratio of 1.81. The firm has a market cap of $1.04 billion, a PE ratio of -5.60 and a beta of 1.48.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 18.71% and a negative return on equity of 57.33%. The business had revenue of $234.42 million during the quarter, compared to the consensus estimate of $220.19 million. During the same quarter in the previous year, the business posted ($0.65) EPS. The company's revenue for the quarter was up 22.3% on a year-over-year basis. As a group, equities research analysts expect that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TNDM has been the subject of a number of recent analyst reports. Wall Street Zen cut Tandem Diabetes Care from a "hold" rating to a "sell" rating in a research report on Saturday, June 21st. Wells Fargo & Company cut their price objective on Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating for the company in a research report on Thursday, May 1st. Citigroup reaffirmed a "sell" rating and issued a $14.00 price objective (down from $24.00) on shares of Tandem Diabetes Care in a research report on Wednesday, July 9th. Stifel Nicolaus cut their price objective on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Finally, Canaccord Genuity Group increased their target price on Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $32.71.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.